Literature DB >> 24298065

Progress in breast cancer: overview.

Carlos L Arteaga1.   

Abstract

This edition of CCR Focus titled Research in Breast Cancer: Frontiers in Genomics, Biology, and Clinical Investigation reviews six topics that cover areas of translational research of high impact in breast cancer. These topics represent areas of breast cancer research where significant progress has occurred but also where very important challenges remain. The papers in this CCR Focus section are contributed by experts in the respective areas of investigation. Herein, key aspects of these contributions and the research directions they propose are reviewed. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24298065     DOI： 10.1158/1078-0432.CCR-13-2549

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  6 in total

1.  High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.

Authors:  K Allenson; J Castillo; F A San Lucas; G Scelo; D U Kim; V Bernard; G Davis; T Kumar; M Katz; M J Overman; L Foretova; E Fabianova; I Holcatova; V Janout; F Meric-Bernstam; P Gascoyne; I Wistuba; G Varadhachary; P Brennan; S Hanash; D Li; A Maitra; H Alvarez
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

2.  Beneficial effects of low dose radiation in response to the oncogenic KRAS induced cellular transformation.

Authors:  Rae-Kwon Kim; Min-Jung Kim; Ki Moon Seong; Neha Kaushik; Yongjoon Suh; Ki-Chun Yoo; Yan-Hong Cui; Young Woo Jin; Seon Young Nam; Su-Jae Lee
Journal:  Sci Rep       Date:  2015-10-30       Impact factor: 4.379

Review 3.  Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.

Authors:  Richard L Schroeder; Cheryl L Stevens; Jayalakshmi Sridhar
Journal:  Molecules       Date:  2014-09-23       Impact factor: 4.411

4.  Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.

Authors:  Suping Zhang; Han Zhang; Emanuela M Ghia; Jiajia Huang; Liufeng Wu; Jianchao Zhang; Sharon Lam; Yang Lei; Jinsong He; Bing Cui; George F Widhopf; Jian Yu; Richard Schwab; Karen Messer; Wenqi Jiang; Barbara A Parker; Dennis A Carson; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-08       Impact factor: 11.205

5.  MEL-18, a tumor suppressor for aggressive breast cancer.

Authors:  Jeong-Yeon Lee; Gu Kong
Journal:  Oncotarget       Date:  2015-06-30

6.  Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.

Authors:  Erik S Knudsen; Agnieszka K Witkiewicz
Journal:  Oncotarget       Date:  2016-10-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.